Reinventing Biotech’s Business Model: The Photo Gallery

NEXT IMAGE >>
Reinventing Biotech’s Business Model — Steve Tregay of Forma Therapeutics described how he scraped together some venture capital, bought some cheap used equipment, and managed to build one of the most prolific drug discovery shops in the pharma industry, when so many other companies are avoiding investments in infrastructure. He’s done it on just $33 million in venture capital, and a lot more from its network of drug company partners.
Photo by Curt Woodward

Pages: Page 1, Page 2, Page 3, Page 4, Page 5, Page 6, Page 7, Page 8, Page 9, Page 10, Page 11, Page 12, Page 13, Page 14, Page 15, Page 16, Page 17, Page 18, Page 19, Page 20, Page 21, Page 22, Page 23, Page 24

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.